Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07739459) titled 'Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)' on July 28.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The Lymphoma Academic Research Organisation
Condition:
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Intervention:
Drug: Zanubrutinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: December 2026
Target Sample Size: 95
Countries of Recruitment:
France
To know more, visit https://c...